Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522354 | 1.00 | MTOR (0.58) | MTORPIK3CARPTORMLST8CD74 | |
| SCHEMBL20017654 | 0.92 | MTOR (0.47) | MTORPIK3CARPTORMLST8CMA1 | |
| SCHEMBL482032 | 0.83 | CMA1 (0.48) | MTORPIK3CARPTORMLST8CMA1 | |
| SCHEMBL136928 | 0.80 | MTOR (0.58) | MTORPIK3CARPTORMLST8CD74 | |
| SCHEMBL29522322 | 0.80 | MTOR (0.58) | MTORPIK3CARPTORMLST8CD74 | |
| SCHEMBL28760862 | 0.80 | CMA1 (0.43) | MTORPIK3CARPTORMLST8CMA1 | |
| SCHEMBL19956323 | 0.80 | MTOR (0.54) | MTORCD74MIFTNIKFYN | |
| SCHEMBL20892260 | 0.76 | MTOR (0.54) | MTORCD74MIFTNIKFYN | |
| SCHEMBL28111872 | 0.75 | CD74 (0.52) | MTORCD74MIFCMA1AADAT | |
| SCHEMBL137477 | 0.73 | MTOR (0.63) | MTORPIK3CARPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131552-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | claimed |
| EP-3131550-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2017-02-02 | — | — | US | claimed |
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | claimed |
| EP-2986318-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2986299-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2986322-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2986297-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2986298-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2986321-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A CYTIDINE ANALOG FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| WO-2014172436-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | claimed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | claimed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | claimed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | claimed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | claimed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | claimed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885PIK3CA 9/4885RPTOR 6/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MTOR 138/4885PIK3CA 590/4885RPTOR 1099/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 10/4885RPTOR 3/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PIK3CA 2787/4885RPTOR 478/4885 |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PIK3CA 2787/4885RPTOR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.